RU2012129882A - Соединение - Google Patents
Соединение Download PDFInfo
- Publication number
- RU2012129882A RU2012129882A RU2012129882/04A RU2012129882A RU2012129882A RU 2012129882 A RU2012129882 A RU 2012129882A RU 2012129882/04 A RU2012129882/04 A RU 2012129882/04A RU 2012129882 A RU2012129882 A RU 2012129882A RU 2012129882 A RU2012129882 A RU 2012129882A
- Authority
- RU
- Russia
- Prior art keywords
- group
- substituted
- compound
- compound according
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 7
- 150000003839 salts Chemical class 0.000 claims abstract 7
- -1 bicyclic heteroaromatic compound Chemical group 0.000 claims abstract 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract 3
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 3
- 239000000460 chlorine Chemical group 0.000 claims abstract 3
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 3
- 239000011737 fluorine Substances 0.000 claims abstract 3
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims abstract 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 150000002367 halogens Chemical group 0.000 claims abstract 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims abstract 2
- 125000001041 indolyl group Chemical group 0.000 claims abstract 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims abstract 2
- 125000005956 isoquinolyl group Chemical group 0.000 claims abstract 2
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims abstract 2
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims abstract 2
- 208000032859 Synucleinopathies Diseases 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 206010003694 Atrophy Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- JTSFIVQMXUDGAB-UHFFFAOYSA-N 4-thiomorpholin-4-ylmorpholine Chemical compound C1COCCN1N1CCSCC1 JTSFIVQMXUDGAB-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 abstract 5
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical group C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 abstract 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Chemical group C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28708209P | 2009-12-16 | 2009-12-16 | |
| US61/287,082 | 2009-12-16 | ||
| PCT/US2010/060862 WO2011084642A1 (en) | 2009-12-16 | 2010-12-16 | Compound suitable for the treatment of synucleopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012129882A true RU2012129882A (ru) | 2014-01-27 |
Family
ID=43629477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012129882/04A RU2012129882A (ru) | 2009-12-16 | 2010-12-16 | Соединение |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8846682B2 (enExample) |
| EP (1) | EP2513090A1 (enExample) |
| JP (2) | JP5922031B2 (enExample) |
| KR (1) | KR20120112548A (enExample) |
| CN (1) | CN102725284A (enExample) |
| AU (1) | AU2010339841B2 (enExample) |
| BR (1) | BR112012014807A2 (enExample) |
| CA (1) | CA2784744A1 (enExample) |
| MX (1) | MX335989B (enExample) |
| NZ (1) | NZ600449A (enExample) |
| RU (1) | RU2012129882A (enExample) |
| WO (1) | WO2011084642A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2830608B8 (en) * | 2012-03-28 | 2020-01-15 | UCB Biopharma SRL | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| US9284309B2 (en) * | 2012-07-16 | 2016-03-15 | Neuropore Therapies, Inc. | Di- and tri-heteroaryl derivatives as inhibitors of protein aggregation |
| WO2014179303A1 (en) * | 2013-04-29 | 2014-11-06 | The General Hospital Corporation | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease |
| AU2015211119B2 (en) | 2014-01-29 | 2019-05-30 | Ucb Biopharma Sprl | Heteroaryl amides as inhibitors of protein aggregation |
| CN104530013B (zh) * | 2014-12-04 | 2016-06-29 | 中国农业大学 | 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途 |
| EP3328379B1 (en) * | 2015-07-29 | 2021-07-28 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
| AU2018213886A1 (en) * | 2017-01-26 | 2019-07-25 | UCB Biopharma SRL | Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation |
| ES2882285T3 (es) * | 2017-01-26 | 2021-12-01 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| KR20190112022A (ko) * | 2017-01-26 | 2019-10-02 | 유씨비 바이오파마 에스피알엘 | 단백질 응집의 조절제로서의 바이사이클릭 비스-헤테로아릴 유도체 |
| US12178805B2 (en) | 2017-05-11 | 2024-12-31 | Remynd N.V. | Inhibitors of PDE6Delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders |
| WO2018206760A1 (en) | 2017-05-11 | 2018-11-15 | Remynd N.V. | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders |
| US20250074902A1 (en) * | 2021-12-27 | 2025-03-06 | Shanghai Jingxin Biomedical Co., Ltd. | Fused bicyclic heteroaryl amide compound as protein aggregation inhibitor |
| TW202415651A (zh) | 2022-07-29 | 2024-04-16 | 日商住友製藥股份有限公司 | 含氮飽和雜環衍生物 |
| TW202412787A (zh) | 2022-07-29 | 2024-04-01 | 日商住友製藥股份有限公司 | 2(1h)-吡啶亞胺衍生物 |
| WO2024102758A2 (en) * | 2022-11-08 | 2024-05-16 | The General Hospital Corporation | N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof |
| WO2025002040A1 (zh) * | 2023-06-25 | 2025-01-02 | 上海京新生物医药有限公司 | 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0726263A3 (en) | 1995-02-08 | 1996-10-09 | American Cyanamid Co | Herbicides (1,3,4) oxadiazoles and thiadiazoles |
| US5591695A (en) | 1995-02-08 | 1997-01-07 | American Cyanamid Co. | Herbicidal [1,3,4]oxadiazoles and thiadiazoles |
| WO1998027108A2 (en) | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
| US6096688A (en) | 1996-12-27 | 2000-08-01 | American Cyanamid Company | Oxazole carboxamide herbicides |
| JP2007519753A (ja) | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| CA2580767A1 (en) * | 2004-09-17 | 2006-03-30 | Whitehead Institute For Biomedical Research | Compounds, compositions and methods of inhibiting alpha-synuclein toxicity |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| KR101394245B1 (ko) * | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| US8541406B2 (en) * | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
| EP2007373A4 (en) * | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
| US8163953B2 (en) * | 2008-04-18 | 2012-04-24 | University Of Connecticut | Compounds for lysosomal modulation and methods of use |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
-
2010
- 2010-12-16 BR BR112012014807A patent/BR112012014807A2/pt not_active IP Right Cessation
- 2010-12-16 US US13/516,543 patent/US8846682B2/en active Active
- 2010-12-16 NZ NZ600449A patent/NZ600449A/en not_active IP Right Cessation
- 2010-12-16 KR KR1020127018232A patent/KR20120112548A/ko not_active Ceased
- 2010-12-16 CN CN2010800568024A patent/CN102725284A/zh active Pending
- 2010-12-16 WO PCT/US2010/060862 patent/WO2011084642A1/en not_active Ceased
- 2010-12-16 RU RU2012129882/04A patent/RU2012129882A/ru not_active Application Discontinuation
- 2010-12-16 MX MX2012006740A patent/MX335989B/es unknown
- 2010-12-16 AU AU2010339841A patent/AU2010339841B2/en not_active Ceased
- 2010-12-16 CA CA2784744A patent/CA2784744A1/en not_active Abandoned
- 2010-12-16 JP JP2012544854A patent/JP5922031B2/ja not_active Expired - Fee Related
- 2010-12-16 EP EP10805668A patent/EP2513090A1/en not_active Withdrawn
-
2014
- 2014-08-21 US US14/465,773 patent/US20140364610A1/en not_active Abandoned
-
2015
- 2015-11-06 JP JP2015218140A patent/JP2016074679A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US8846682B2 (en) | 2014-09-30 |
| AU2010339841B2 (en) | 2014-09-25 |
| NZ600449A (en) | 2014-10-31 |
| BR112012014807A2 (pt) | 2017-06-27 |
| US20130035342A1 (en) | 2013-02-07 |
| KR20120112548A (ko) | 2012-10-11 |
| JP5922031B2 (ja) | 2016-05-24 |
| JP2013514980A (ja) | 2013-05-02 |
| JP2016074679A (ja) | 2016-05-12 |
| EP2513090A1 (en) | 2012-10-24 |
| CN102725284A (zh) | 2012-10-10 |
| US20140364610A1 (en) | 2014-12-11 |
| MX335989B (es) | 2016-01-07 |
| WO2011084642A1 (en) | 2011-07-14 |
| AU2010339841A1 (en) | 2012-07-05 |
| CA2784744A1 (en) | 2011-07-14 |
| MX2012006740A (es) | 2012-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012129882A (ru) | Соединение | |
| ES2795366T3 (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas | |
| KR101921404B1 (ko) | 신규 2치환 1,2,4-트리아진 화합물 | |
| US8809552B2 (en) | Azetidine compounds, compositions and methods of use | |
| BRPI0620201A2 (pt) | derivados de pirimidina | |
| RU2007119307A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[3, 2-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В ТЕРИПИИ | |
| ES2973331T3 (es) | Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo | |
| MA30360B1 (fr) | Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k | |
| RU2007119373A (ru) | Фармацевтические соединения | |
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
| NZ572600A (en) | 6-Amino-purine derivatives for the treatment of cancer and fibrogenetic disorders | |
| HRP20120077T1 (hr) | Benzimidazolonski spojevi s aktivnošću agonista 5-ht4 receptora | |
| NZ599860A (en) | Carboxamide compounds and their use as calpain inhibitors | |
| EP2590981A1 (en) | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| KR20100045440A (ko) | 11-베타 하이드록실 스테로이드 데하이드로게나제 1형의 억제제로서의 스피로사이클 | |
| EP1499598A1 (en) | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions | |
| JP2011510929A5 (enExample) | ||
| MX2009010884A (es) | 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k). | |
| WO2006040966A1 (ja) | 芳香環縮合ピリミジン誘導体 | |
| NZ603896A (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
| JP2012507525A5 (enExample) | ||
| CZ56298A3 (cs) | 2,3-dioxo-1,2,3,4-tetrahydrochinoxalinylové deriváty, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje | |
| JP2014530807A (ja) | Ｈ３受容体阻害剤としてのピペリジン及びピペラジン環を含むカルバメート／尿素誘導体 | |
| HUP0201937A2 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20141224 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161108 |